ロード中...
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin
BACKGROUND: There is no proven primary preventive strategy for doxorubicin‐induced subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) risk. We investigated the primary preventive effect on DISC of the concomitant use of angiotensin receptor blockers (ARBs) or...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8209607/ https://ncbi.nlm.nih.gov/pubmed/33998163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3956 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|